Cancer Biological Therapy Market

Cancer Biological Therapy Market by Products (Monoclonal Antibodies [Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, and Bispecific Monoclonal Antibodies], Vaccines [Preventive Vaccines and Therapeutic Vaccines], Cancer Growth Blockers [Tyrosine Kinase Inhibitors, Proteasome Inhibitors, and mTOR Inhibitors], Blood Cell Growth Factors [Lenograstim and Filgrastim], and Cytokines [Interferons and Interleukins]), Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Mail Order Pharmacies), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021–2028

  • Report ID: HC-1002
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 2
  • No. Of Pages: 150
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global cancer biological therapy market size is projected to register a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the growing prevalence of several cancers across the globe.

Cancer Biological Therapy Market Key Takeaways

Biological therapy involves a range of treatment process that use living organism substances obtained from either living organisms or laboratory variations of the substances to cure a particular disease. So, cancer biological therapy relies on the treatment process of using living organism components to fight cancer. The therapy generally consists of several treatment products such as interleukins, interferons, monoclonal antibodies, vaccines, and others, which help in the implementation of effective cancer treatment. In other words, it directly or indirectly utilizes the immune system of a body in order to fight cancer or use of bacteria to regulate antibodies for action against cancer cells. The treatment is considered to be effective without compromising the healthy cells. For instance, the monoclonal antibodies perform its action by either reducing the cancer growth or increasing cell death.

The emergence of COVID-19 pandemic has temporarily paused cancer treatment across the globe. Additionally, cancer patients are considered to be at high risk of the novel coronavirus due to weak immune system. The emergency lockdown imposed in various countries to control the virus spread has led to supply chain disruptions of immunotherapy drugs and has adversely affected the market growth.

Market Drivers, Restraints, Trends, and Opportunities

  • Increasing investment in research and development and emerging markets for biological therapies are projected to drive the market growth during the forecast period.
  • Increasing number of cancer cases and rising number of the aging population across the globe are projected to drive the market growth.
  • Increasing demand for biological and targeted drug therapy along with continuous patent expiry of cancer drugs are anticipated to positively impact the market growth during the forecast period.
  • High expenditure on drug development, negative impacts of cancer drug therapy, and the risk of treatment failure are key challenges that can hinder the market growth.  
  • Complicated reimbursement policies and stringent government guidelines for approval of devices or drugs are projected to hamper the market growth in the coming years.
  • Increasing use of nanotechnology and other advanced technology in the development of treatment devices and equipment are projected to create large opportunities for the market growth during the forecast period.

Scope of the Report

The report on the global cancer biological therapy market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Cancer Biological Therapy Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Products (Monoclonal Antibodies [Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, and Bispecific Monoclonal Antibodies], Vaccines [Preventive Vaccines and Therapeutic Vaccines], Cancer Growth Blockers [Tyrosine Kinase Inhibitors, Proteasome Inhibitors, and mTOR Inhibitors], Blood Cell Growth Factors [Lenograstim and Filgrastim], and Cytokines [Interferons and Interleukins]) and Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Mail Order Pharmacies)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Amgen Inc., Bristol-Myers Squibb, Celgene Corporation, F. Hoffmann-La Roche AG, Novartis International AG, Merck & Co., Inc., GlaxoSmithKline Plc, Eli Lilly, Spectrum Pharmaceuticals, Inc., and Seattle Genetics, Inc.


Global Cancer Biological Therapy Market Segment Insights

Vaccines segment is projected to constitute a large market share
On the basis of products, the cancer biological therapy market is divided into monoclonal antibodies, vaccines, cancer growth blockers, blood cell growth factors, and Cytokines. The monoclonal antibodies segment is further segmented into naked monoclonal antibodies, conjugated monoclonal antibodies, and bispecific monoclonal antibodies. The vaccines segment is further classified as preventive vaccines and therapeutic vaccines while the cancer growth blockers consists of tyrosine kinase inhibitors, proteasome inhibitors, and mTOR inhibitors. The blood cell growth factors segment is sub-segregated into lenograstim and filgrastim while the cytokines segment is bifurcated as interferons and interleukins.

The vaccines segment is projected to constitute a large market share during the forecast period owing to the growing prevalence of cancer across the globe along with rising awareness about preventive measures for cancer. Additionally, increasing demand for preventive vaccines such as human papilloma vaccines (HPV) and hepatitis B vaccines (HBV) is expected to further spur the segment growth. Furthermore, utilizing therapeutic cancer vaccines to reduce the growth of relapsed tumors is projected to propel the segment growth during the forecast period. Meanwhile, the monoclonal antibodies segment is expected to expand at a high CAGR during the forecast period due to the wide demand for the products since these monoclonal antibodies are able to target specific proteins on the cell surface. Additionally, growing inclination of patients towards advanced cancer biological therapy to avoid risks associated with anti-cancer drug therapy is projected to further drive the segment growth.

Hospitals pharmacies segment is anticipated to account for a considerable market share
Based on distribution channels, the market is segregated into hospitals pharmacies, retail pharmacies, and mail order pharmacies. The hospitals pharmacies segment is anticipated to account for a considerable market share during the forecast period owing to the patients’ preference to undergo treatment at hospitals. Wide availability of an extensive range of medical devices for surgeries and treatments and the presence of high-specialized doctors for the treatment are the key factors boosting the segment growth. The significant growth in the number of cancer research centers and laboratories is further propelling the segment growth during the forecast period. Additionally, substantial funding by the government and private firms across the globe is further driving the segment growth.

Cancer Biological Therapy Market By Distribution Channels

North America is expected to exhibit a high CAGR
In terms of regions, the cancer biological therapy market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to account for a significant market share during the forecast period owing to the rising investments in research and development and the establishment of various healthcare initiatives in the region. Additionally, increasing disposable income of people along with the presence of a large number of cancer biological drug and vaccine manufacturers act as key factors boosting the market growth in the region. Moreover, wide availability of affordable cancer treatment facility and rising number of health insurance coverage for serious diseases are further propelling the regional market growth.

The market of Asia Pacific is expected to expand at a healthy CAGR during the forecast period owing to the growing occurrence of cancer, enhanced healthcare facilities, and a large patient pool in the region. In Asia Pacific, Japan is a major market, contributing to a large share in the cancer treatment market.

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Cancer Biological Therapy Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Cancer Biological Therapy Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Cancer Biological Therapy Market - Supply Chain
  4.5. Global Cancer Biological Therapy Market Forecast
     4.5.1. Cancer Biological Therapy Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Cancer Biological Therapy Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Cancer Biological Therapy Market Absolute $ Opportunity
5. Global Cancer Biological Therapy Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Cancer Biological Therapy Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Cancer Biological Therapy Demand Share Forecast, 2019-2026
6. North America Cancer Biological Therapy Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Cancer Biological Therapy Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Cancer Biological Therapy Demand Share Forecast, 2019-2026
7. Latin America Cancer Biological Therapy Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Cancer Biological Therapy Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Cancer Biological Therapy Demand Share Forecast, 2019-2026
8. Europe Cancer Biological Therapy Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Cancer Biological Therapy Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Cancer Biological Therapy Demand Share Forecast, 2019-2026
9. Asia Pacific Cancer Biological Therapy Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Cancer Biological Therapy Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Cancer Biological Therapy Demand Share Forecast, 2019-2026
10. Middle East & Africa Cancer Biological Therapy Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Cancer Biological Therapy Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Cancer Biological Therapy Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Cancer Biological Therapy Market: Market Share Analysis
  11.2. Cancer Biological Therapy Distributors and Customers
  11.3. Cancer Biological Therapy Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Amgen Inc. Bristol-Myers Squibb Celgene Corporation F. Hoffmann-La Roche AG Novartis International AG Merck & Co., Inc. GlaxoSmithKline Plc Eli Lilly
Segments Covered in the Report
The global cancer biological therapy market has been segmented on the basis of

Products
  • Monoclonal Antibodies
    • Naked Monoclonal Antibodies
    • Conjugated Monoclonal Antibodies
    • Bispecific Monoclonal Antibodies
  • Vaccines
    • Preventive Vaccines
    • Therapeutic Vaccines
  • Cancer Growth Blockers
    • Tyrosine Kinase Inhibitors
    • Proteasome Inhibitors
    • mTOR Inhibitors
  • Blood cell growth factors
    • Lenograstim
    • Filgrastim
  • Cytokines
    • Interferons
    • Interleukins
Distribution Channels
  • Hospital Pharmacies
  • Retail Pharmacies
  • Mail Order Pharmacies
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Amgen Inc.
  • Bristol-Myers Squibb
  • Celgene Corporation
  • F. Hoffmann-La Roche AG
  • Novartis International AG
  • Merck & Co., Inc.
  • GlaxoSmithKline Plc
  • Eli Lilly
  • Spectrum Pharmaceuticals, Inc.
  • Seattle Genetics, Inc.

Some of the key players in the global cancer biological therapy market include Amgen Inc., Bristol-Myers Squibb, Celgene Corporation, F. Hoffmann-La Roche AG, Novartis International AG, Merck & Co., Inc., GlaxoSmithKline Plc, Eli Lilly, Spectrum Pharmaceuticals, Inc., and Seattle Genetics, Inc.

These key players are paying their focus on adoption of various strategic initiatives such as new product launch, mergers, and acquisitions to strengthen their existing market position. For instance, in December 2018, GlaxoSmithKline announced the acquisition of TESARO, an oncology-focused biopharmaceutical company. This acquisition was aimed at helping the former company to further enhance its oncology business operation across the globe.

Cancer Biological Therapy Market By Key Players

Buy Report